Skip to main content

Table 1 Some clinical data on the groups of subjects studied. Median and 25th and 75th percentile values are reported in brackets

From: Cross-sectional and prospective study on anti-Müllerian hormone changes in a cohort of pre-menopausal women with a history of differentiated thyroid cancer

 Group 1
n = 59
Group 2
n = 30
Group 3
n = 141
Significance P
Age (years)41.2 ± 7.5 (43; 37–47)42.4 ± 9.2 (45; 40–49)33.1 ± 10.1 (33; 24–42)< 0.0001; a
Mother’s age on menopause (years)51.0 ± 4.2 (51; 50–54)51.1 ± 4.2 (51; 49–55)50.1 ± 4.2 (51; 48–52)0.57
Time since primary treatments (years)7.2 ± 6.8 (5: 2–9)4.6 ± 4.1 (3; 1–7)n.a.0.07
BMI (kg/m2)25.3 ± 6.0 (23.5; 21.6–27.0)24.2 ± 6.0 (23.5; 21.6–27.0)24.5 ± 6.5 (23.8; 21.0–25.3)0.45
Cumulative RAI activity (mCi)100.1 ± 117.4 (80; 60–100)n.a.n.a.
Cured (%) / Biochemical disease (%)97/3100/0n.a.0.55
L-T4 dosage (μg/week)859.1 ± 157.3 (825; 775–925)741.3 ± 148.4 (725; 644–875)n.a.0.001
TSH (mIU/l)0.46 ± 0.83 (0.17; 0.04–0.42)1.69 ± 1.78 (1.37; 0.25–2.31)2.35 ± 1.79 (2.11; 1.23–2.81)< 0.0001; b, c
f-T4 (pmol/l)20.5 ± 4.9 (20.7; 18.1–23.2)16.5 ± 3.9 (16.4; 15.2–19.0)13.8 ± 3.3 (13.4; 11.4–16.7)< 0.0001; d, e, f
Tg (μg/l)0.24 ± 0.47 (0.20; 0.04–0.20)1.32 ± 3.20 (0.20; 0.09–0.67)n.d.0.01
TgAb positive (%)24n.d.0.17
  1. (When ANOVA was significant, differences among groups were evaluated by means of Dunn’s test. Age: (a) group 3 vs group 1 and group 2, both P < 0.0001. TSH: (b) group 1 vs group 2, P = 0.03; (c) group 1 vs group 3, P < 0.0001. Free-T4: (d) group 1 vs group 2, P = 0.003; (e) group 1 vs group 3, P < 0.0001; (f) group 2 vs group 3, P = 0.003. Evaluation not applicable: n.a.; evaluation not done: n.d.)